Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer
Annals of Nuclear Medicine · 2025
DOI: 10.1007/s12149-024-01990-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Qaid Ahmed Shagera und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Rue Meylemeersch 90, …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Positron Emission Tomography Computed Tomography, Radium, Edetic Acid. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
AIM: Conventional imaging techniques and prostate-specific antigen (PSA) values are not useful to follow-up patients during Radium-223 treatment. The study aimed to evaluate the predictive value of prostate-specific membrane antigen PSMA PET/CT-based response in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Radium-223 dichloride treatment. MATERIALS AND METHODS: Patients treated with radium-223, having performed two 68Ga-PSMA-11 PET/CT scans (baseline 1 month before treatment initiation and follow-up 2 weeks after the third cycle), were retrospectively evaluated. Visual and quantitative PET image analyses were performed, and patients were dichotomized into progressive (PD) and non-PD according to Response Evaluation Criteria in PSMA‑imaging (RECIP1.0) and PSMA-PET Progression criteria (PPP). The primary endpoint was overall survival (OS). Cohen's Kappa (κ) was used to test the agreement between the two criteria. The Cox regression hazard model and Kaplan-Meier method were used for survival analyses. RESULTS: Twenty-eight mCRPC patients were evaluated. Sixteen (43%) and 18 (64%) patients had PD according to RECIP1.0 and PPP, respectively; κ = 0.85 (95% CI 0.65-1.00). After a median follow-up of 16 months (interquartile IQR 9-33), 20 (71%) patients died. Patients with PSMA PD showed a higher risk of death than non-PD according to RECIP1.0 (HR = 2.9; 95% CI 1.14-7.46; p = 0.029) and PPP (HR = 2.8; 95% CI 1.04-7.64; p = 0.042). For both criteria, the median OS was shorter for PD than non-PD (37 vs. 12 months, Log-rank; p < 0.05). The C-index for RECIP1.0 and PPP were almost equal (0.66 and 0.63; respectively). CONCLUSION: This study demonstrated that PSMA-PET/CT imaging is valuable for monitoring radium-223 treatment. Both PSMA PET/CT response criteria (RECIP1.0 and PPP) perform similarly predicting OS at follow-up after three cycles of radium-223. These findings urge further validation in prospective trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Rue Meylemeersch 90, 1070, Brussels, Belgium.
- Department of Oncology, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Department of Oncology, CHU Saint Pierre, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Data Centre, Unité de Gestion de L'Information (UGI), Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Department of Urology, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Brussels, Belgium.
- Department of Nuclear Medicine, Institut Jules Bordet, Hopital Universitaire de Bruxelles, Université Libre de Bruxelles (ULB), Rue Meylemeersch 90, 1070, Brussels, Belgium. carlos.artigas@hubruxelles.be.
Zitieren
APA
Shagera, Q. A., Gil, T., Barraco, E., Boegner, P., Kristanto, P., El Ali, Z., Sideris, S., Martinez Chanza, N., Roumeguère, T., Flamen, P., & Artigas, C. (2025). Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-024-01990-w
Vancouver
Shagera QA, Gil T, Barraco E, Boegner P, Kristanto P, El Ali Z, et al. Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-024-01990-w
BibTeX
@article{Shagera2025,
author = {Shagera, Qaid Ahmed and Gil, Thierry and Barraco, Elisa and Boegner, Petra and Kristanto, Paulus and El Ali, Ziad and Sideris, Spyridon and Martinez Chanza, Nieves and Roumeguère, Thierry and Flamen, Patrick and Artigas, Carlos},
title = {Evaluating response to radium-223 using 68Ga-PSMA PET/CT imaging in patients with metastatic castration-resistant prostate cancer},
journal = {Annals of Nuclear Medicine},
year = {2025},
doi = {10.1007/s12149-024-01990-w}
}
EUVIMED